Edition:
United States

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

4Sc AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

27 Aug 2016 Reuters Investment Profile 12 $20.00

Wright Investors Service Comprehensive Report for 4Sc AG

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

22 Aug 2016 Wright Reports 61 $75.00

4SC - FOCUS ON PHASE II CTCL LAUNCH, Q416

H1 results were in line with our expectations and primarily underscored the potential importance of more detailed analysis of...

15 Aug 2016 Edison Investment Research 3 $10.00

4SC - INCREASED FOCUS ON CORE BUSINESS

4SC’s Q1 results highlight an increased focus on its core business of epigenetic research and commercialisation, resulting fr...

19 May 2016 Edison Investment Research 3 $10.00

EQUI-Peers: Biotech - Krebstherapien

EQUITS GmbH, Frankfurt, setzt ihre neue Analyse-Reihe 'EQUI-Peer' mit einer weiteren Peergroup-Analyse 'EQUI-Peer Biotech - ...

16 Dec 2015 EQUI.TS 9 $25.00

EQUI-Peer: Biotech - Cancer Therapies

EQUITS GmbH continues its innovative Research series. 'EQUI-Peer Biotech - Cancer therapies provides a peer group compariso...

16 Dec 2015 EQUI.TS 10 $25.00

4 Sc AG: Downgraded to Average

10 Dec 2015 Sadif Analytics Prime 3 $10.00

4SC AG - RESMINOSTAT REFOCUSED CANCER STRATEGY

4SC has fresh funds and a renewed clinical strategy for its lead epigenetic anti-cancer agent resminostat. A €29m (gross) cap...

09 Nov 2015 Edison Investment Research 2 $10.00

4 Sc AG: Downgraded to Risky

03 Aug 2015 Sadif Analytics Prime 3 $10.00

4 Sc AG: Upgraded to Average

06 May 2015 Sadif Analytics Prime 3 $10.00